Rexahn obtains additional patent coverage for anti-cancer candidate RX-1792 in Japan

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled "Quinazoline Derivatives and Therapeutic Use Thereof." This new patent covers Rexahn's anti-cancer candidate RX-1792 and related compounds, and a composition for treating anti-proliferative and anti-tumor activities.

“We are very pleased to obtain this additional patent coverage for RX-1792 in Japan, which broadens and strengthens our global intellectual property position. RX-1792 continues to demonstrate exciting anti-proliferative and anti-tumor effects in preclinical studies, and we look forward to accelerating its development.”

Rick Soni, President of Rexahn, noted, "We are very pleased to obtain this additional patent coverage for RX-1792 in Japan, which broadens and strengthens our global intellectual property position. RX-1792 continues to demonstrate exciting anti-proliferative and anti-tumor effects in preclinical studies, and we look forward to accelerating its development."

Preclinical studies have shown that RX-1792 inhibits in vitro proliferation of cancer cells derived from human solid tumors, including drug-resistant cells, by inhibiting EGFR tyrosine kinase. RX-1792 has also inhibited tumor growth in xenograft human tumor models.